Agency: National Aeronautics and Space Administration | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 749.48K | Year: 2014
The goal of this proposed program through Phase III is to build a space-worthy Drug Stability Analyzer that can determine the extent of drug degradation. It will be able to monitor the drug active pharmaceutical ingredient (API) and its degradation product concentrations as a function of time, as well as determine if a drug is suitable for use. This will be accomplished by designing and building a rugged, small, low mass, low power, easy to use analyzer that can identify and quantify API and degradation products with little or no sample handling in 1 minute. Feasibility was successfully demonstrated during Phase I by measuring acetaminophen, azithromycin, epinephrine, lidocaine, and their degradation products in mixtures and during reaction with a 1-4% limit of detection. The API's were also successfully measured in commercial products. During the Phase II program a prototype Drug Stability Analyzer, suitable for space deployment will be built and used to measure the degradants of all the ISS medical kit drugs (>100) with an accuracy goal of 2% and a precision goal of 1% within 1 minute. The Drug Stability Analyzer will be transitioned from a TRL 3 to a 7 (ground tested).
Agency: Department of Defense | Branch: Navy | Program: SBIR | Phase: Phase II | Award Amount: 750.00K | Year: 2011
The goal of this Phase II program is to bring the Marine Corps (RTA) Fuel Analyzer to a readiness level sufficient for production. This will accomplished by building three test units to establish temperature use range and validate fuel property analysis.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 156.53K | Year: 2012
DESCRIPTION (provided by applicant): The overall aim of this SBIR program is to develop a surface-enhanced Raman spectroscopy (SERS) based device for on-site analysis of drugs in saliva. This device will allow immediate assessment of both medicinal and illicit drug use by patients with substance-related disorders (SRDs), and provide medical professionals and management with quantitative data so that treatment decisions can be made. Successful treatments for SRD patients require frequent monitoring of both medicinal and illicit drug use, which are mostly done in outpatient settings (doctor's office, rehabilitation centers, etc.) employing urine- based drug tests. For such tests, a sample is screened with immunoassay test kits, and if a drug is present, it isconfirmed and quantified by gas chromatography - mass spectrometry (GC-MS). Unfortunately, immunoassay test kits are susceptible to false positives, while the GC-MS method is time consuming and requires highly trained operators and a laboratory setting. Consequently, there is a critical need for a device that combines the portability, speed and ease-of-use of immunoassay kits with the identification and quantitation abilities of GC-MS so that health care personnel can assess SRD patient compliance in outpatient settings. The proposed SERS Saliva Analyzer (SSA) will meet all such requirements by providing health care personnel an easy-to-use device, which will extract, identify and quantify the presence of drugs (and metabolites) at requisite levels in saliva(1-50 ng/mL), within 10 minutes. The overall aim of the Phase I program is to demonstrate feasibility by detecting two priority drugs (cocaine and diazepam) in saliva at physiologically relevant concentrations and analysis time. This will be accomplishedby 1) measuring cocaine and diazepam at required sensitivity, and 2) measuring cocaine and diazepam in saliva. PUBLIC HEALTH RELEVANCE: The overall aim of this SBIR program is to develop a surface-enhanced Raman spectroscopy (SERS) based device foron-site analysis of drugs in saliva. This device will allow immediate assessment of both medicinal and illicit drug use by patients with substance-related disorders (SRDs), and provide medical professionals and management with quantitative data so that treatment decisions can be made.
Agency: Department of Defense | Branch: Army | Program: SBIR | Phase: Phase II | Award Amount: 999.26K | Year: 2015
The overall goal of this proposed program (through Phase III) is to develop an innovative Portable Fuel Quality Analyzer (PFQA) capable of providing a final fuel quality check of jet and diesel fuels at the point-of-use as either a stand-alone analyzer or
Agency: Department of Defense | Branch: Army | Program: SBIR | Phase: Phase I | Award Amount: 100.00K | Year: 2011
The overall goal of this proposed program (through Phase III) is to develop a chemical warfare agent analyzer capable of detecting vapor phase agents at 10-7g/m3 in less than 1 minute. This will be accomplished by developing a method to produce novel localized surface plasmon resonance (LSPR) nanostructures, supported by theory, that produce a minimum surface-enhanced Raman scattering (SERS) enhancement of 1010, and incorporating them into an air collection sampling system coupled to a field-usable Raman spectrometer. Feasibility will be demonstrated during Phase I by developing and identifying LSPR structures that produce SERS with enhancement factors of 106 and greater using three chemicals, benzenethiol, dimethyl methylphosphonate, and methylphosphonic acid. 2-chloroethyl ethylsulfide will be measured in the vapor phase during an option task. The overall goal of the Phase II program will be to develop a prototype analyzer that can measure 10 chemical agent simulants at 10-7g/m3 concentration in less than 1 minute. This will be accomplished by optimizing the enhancement of the LSPR substrates (through theory and manufacturing), incorporating them into an air collection system coupled to a Raman spectrometer, and quantifying sensitivity. The Phase III program will focus on measuring real chemical agents and developing a field testable system.